| Univariable | Multivariable | ||||
---|---|---|---|---|---|---|
β | 95% CI | p | β | 95% CI | p | |
Age (yrs) | 0.023 | − 0.011, 0.056 | 0.188 | 0.021 | − 0.010, 0.053 | 0.189 |
Disease Duration (yrs) | 0.009 | −0.023, 0.040 | 0.591 | −0.013 | − 0.048, 0.022 | 0.477 |
Gender | ||||||
 • Female | – | – | – | – | – | – |
 • Male | −0.003 | −0.083, 0.077 | 0.942 | −0.012 | −0.086, 0.062 | 0.750 |
Smoking History | ||||||
 • No | – | – | – | – | – | – |
 • Yes | 0.001 | −0.076, 0.078 | 0.979 | 0.018 | − 0.054, 0.090 | 0.621 |
BMI | −0.008 | − 0.045, 0.029 | 0.666 | 0.002 | −0.033, 0.037 | 0.910 |
DMT | ||||||
 • Untreated | – | – | – | – | – | – |
 • Interferon-β | −0.166 | − 0.236, − 0.096 | < 0.001 | − 0.163 | −0.233, − 0.093 | < 0.001 |
 • Cyclophosphamide | 0.268 | 0.147, 0.389 | < 0.001 | 0.274 | 0.152, 0.395 | < 0.001 |
 • Fingolimod | 1.044 | 0.767, 1.320 | < 0.001 | 1.047 | 0.770, 1.323 | < 0.001 |
 • Glatiramer Acetate | −0.082 | −0.187, 0.024 | 0.131 | −0.079 | −0.185, 0.027 | 0.142 |
 • Mycophenolate | −0.072 | −0.181, 0.037 | 0.197 | −0.075 | − 0.184, 0.035 | 0.181 |
 • Natalizumab | −0.529 | −0.647, − 0.411 | < 0.001 | −0.526 | − 0.644, − 0.408 | < 0.001 |
 • Other | − 0.009 | −0.141, 0.124 | 0.900 | −0.012 | − 0.144, 0.121 | 0.862 |
CES-D | 0.034 | 0.008, 0.061 | 0.012 | 0.030 | 0.004, 0.055 | 0.022 |
MFIS | 0.045 | 0.012, 0.078 | 0.008 | 0.035 | 0.004, 0.066 | 0.029 |
MSSS | −0.019 | −0.047, 0.010 | 0.203 | −0.021 | −0.048, 0.006 | 0.121 |
SF-36 Physical QOL | −0.055 | −0.086, − 0.024 | < 0.001 | −0.037 | − 0.067, − 0.007 | 0.015 |
SF-36 Mental QOL | − 0.024 | −0.050, 0.003 | 0.086 | −0.024 | − 0.049, 0.002 | 0.066 |